Metagenomi Therapeutics (MGX) Accumulated Expenses (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Accumulated Expenses data on file, last reported at $1.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.3 million, down 78.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 78.99% YoY), and the FY2025 annual result was $6.7 million, down 20.22% from the prior year.
• Accumulated Expenses eased to $1.3 million in Q1 2026 per MGX's latest filing, from $6.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.5 million in Q4 2023 and troughed at $1.3 million in Q1 2026.
• A 4-year average of $7.7 million and a median of $7.8 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses gained 11.96% in 2025, then plunged 78.99% in 2026.
• A 4-year view of Accumulated Expenses shows it stood at $11.5 million in 2023, then decreased by 26.59% to $8.4 million in 2024, then declined by 20.22% to $6.7 million in 2025, then slumped by 80.86% to $1.3 million in 2026.
• Business Quant data shows MGX's Accumulated Expenses at $1.3 million in Q1 2026, $6.7 million in Q4 2025, and $9.9 million in Q3 2025.